Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaar5012. doi: 10.1126/scitranslmed.aar5012.

2.

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.

Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L.

Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10.

3.

Strategies to Inhibit Myc and Their Clinical Applicability.

Whitfield JR, Beaulieu ME, Soucek L.

Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Review.

4.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

5.

The effect of environmental chemicals on the tumor microenvironment.

Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan EP, Ryeom S, Salem HK, Scovassi AI, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH, Felsher DW.

Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.

6.

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L.

Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852.

7.

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.

Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L.

Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632.

8.

Diet and proinflammatory cytokine levels in head and neck squamous cell carcinoma.

Arthur AE, Peterson KE, Shen J, Djuric Z, Taylor JM, Hebert JR, Duffy SA, Peterson LA, Bellile EL, Whitfield JR, Chepeha DB, Schipper MJ, Wolf GT, Rozek LS.

Cancer. 2014 Sep 1;120(17):2704-12. doi: 10.1002/cncr.28778. Epub 2014 May 15.

9.

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI.

Genes Dev. 2013 Mar 1;27(5):504-13. doi: 10.1101/gad.205542.112.

10.

Tumor microenvironment: becoming sick of Myc.

Whitfield JR, Soucek L.

Cell Mol Life Sci. 2012 Mar;69(6):931-4. doi: 10.1007/s00018-011-0860-x. Epub 2011 Oct 28. Review.

11.

4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.

Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM, Chang AE.

J Immunother. 2007 May-Jun;30(4):406-16.

PMID:
17457215
12.

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.

Clin Cancer Res. 2002 Apr;8(4):1021-32.

16.

Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response.

Kaplan MH, Whitfield JR, Boros DL, Grusby MJ.

J Immunol. 1998 Feb 15;160(4):1850-6.

Supplemental Content

Loading ...
Support Center